drugset / Trial / NCT02214004
Neoadjuvant Trastuzumab and Letrozole for Postmenopausal Women
Phase 2
Unknown
132 enrolled
Gangnam Severance Hospital
Asan Medical Center · collabSamsung Medical Center · collabSeoul National University Hospital · collabSeverance Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate whether trastuzumab and letrozole are effective and safe in the preoperative treatment for postmenopausal patients with hormone receptor-positive and HER2-positive breast cancer.
Timeline
- Start
- 2015-03
- Primary completion
- 2019-03
- Completion
- 2019-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Letrozole | Other / unclassified | 2.5 mg | — |
| Subject | Trastuzumab | Monoclonal antibody | 6 mg/kg | Intravenous |